CV2 Antibody, IgG by CBA-IFA With Reflex to Titer, Serum
Also known as: CV2 SER
Use
CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
Special Instructions
If CV2 Antibody IgG Screen by IFA is positive, then CV2 Antibody IgG Titer by IFA will be added. Additional charges apply.
Limitations
A negative test result does not exclude the diagnosis of autoimmune neurological disease. The results should be interpreted in light of the clinical findings and other laboratory tests. The test utilizes CV2 transfected cell lines for detection and semiquantification, which may have inherent limitations with regards to sensitivity and specificity.
New York Approved
Methodology
Immunoassay (Cell-based)
Biomarkers
LOINC Codes
- 72504-4
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.25 mL
Container
Serum separator tube (SST) or plain red
Storage Instructions
Refrigerated
Causes for Rejection
Hemolyzed, contaminated, or severely lipemic specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |